Praxis Precision Medicines to Present at Stifel’s 3rd Annual CNS Day

CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that management will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on Wednesday, March 31, 2021 at 8:30 a.m. ET.

The fireside chat will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About PraxisPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.

Investor Contact:
Alex Kane
Praxis Precision Medicines
[email protected]
617-300-8481

Media Contact:
Ian Stone
Canale Communications
[email protected]
619-849-5388

You May Also Be Interested In

• HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
• Montage Gold achieves first gold pour at its Koné mine on budget and ahead of schedule
• Zcash Price Prediction: ZEC Targets $1,750 as AlphaPepe Counts Down to a New CEX Reveal Within Two Weeks